Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation
Our research by Dr Tang et al associates NRP1 expression with shorter relapse- and metastasis-free survival, which implicates NRP1 with the aggressive phenotype of claudin-low breast cancer and offers a novel targeted therapeutic approach to this poor prognosis subtype.
